

SUPPLEMENT

Supplemental Table S1. Baseline Characteristics and Outcome by Participant.

	V001	V002	V003	V004	V005	V007	V008	V009	V010	V011	V012	V013	V017
Randomization group	P	V	P	P	V	P	V	P	V	P	V	V	P
Previous arteriovenous access	Yes	Yes	Yes	No	Yes	No	No	Yes	Yes	Yes	No	Yes	Yes
Currently on hemodialysis	Yes	Yes	Yes	No	Yes	No	No	Yes	Yes	Yes	No	Yes	Yes
Diabetes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	No	Yes
Coronary artery disease	Yes	No	No	No	No	No	No	No	No	No	No	No	No
Congestive heart failure	Yes	No	No	No	No	No	No	No	No	No	No	No	Yes
Peripheral artery disease	No	No	No	No	No	No	No	No	No	No	No	No	No
Hypertension	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Ejection Fraction (%)	58	-	-	66	-	-	-	60	63	-	55	50	37
Systolic blood pressure [mmHg]	158	138	132	157	155	125	133	129	144	152	115	102	102
Diastolic blood pressure [mmHg]	77	81	65	82	86	86	86	81	90	90	69	79	77
Heart rate [beats/min]	62	103	76	78	80	73	89	81	100	80	81	83	82
Hemoglobin [g/dl]	12.8	13.0	12.2	6.5	9.0	-	13.3	12.4	12.0	-	11.9	14.9	10.2
Hematocrit [%]	39	40	37	19	295	-	41	38	38	-	38	45	33
Platelet count [1000/microl]	269	164	333	195	212	-	203	232	177	-	234	190	233
INR	1.1	-	-	-	-	-	-	-	1.2	-	1.1	-	1.3
Aspirin 81mg or less	Yes	Yes	No	No	No	No	Yes	No	No	No	Yes	Yes	Yes
Location of fistula	RC	BC	BC	BB	BB	RC	RC	BB	BC	BC	BB	RC	BC
Calcification	Mod.	Normal	Normal	Normal	Normal	Mild	Normal	Normal	Normal	Mild	Normal	Normal	Normal
Palpable thrill at completion	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Bruit at completion	Yes	No	Yes	Yes	No	Yes	Yes	No	No	No	Yes	No	Yes
Time to AV fistula functional maturation or censoring (days from randomization)	198±	169±	145	84	96	197±	169±	48	77	76	238	287±	197±

AVF use within 180 days	No	No	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	No	No
Patency within 180 days +/- 4 weeks	Yes	No^	Yes	Yes	Yes	Yes	No	Yes	No^^	No	No	No^^^	No
Maturation within 180 days +/- 4 weeks	Yes	No	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No*	No**	No
Vein diameter within 180 days +/- 4 weeks	5.5	8.6‡	8.4	5.9	13	5.9	2.3‡	14.9	8.7‡	4.8	-	6.3‡	-
Vein velocity within 180 days +/- 4 weeks	156	124‡	90	75	269	143	501‡	149	111‡	403	-	127‡	-
Any serious adverse event	No	No	No	Yes	No	Yes	No	No	Yes	No	Yes	Yes	Yes
Bleeding	No	No	No	No	No	No	No	No	No	No	No	No	Yes
Death	No	No	No	No	No	No	No	No	No	No	No	No	No
P=Placebo; V=Vorapaxar ±Censored; no AV fistula functional maturation *Fistula maturation 324 days after randomization; **Fistula maturation 287 days after randomization ^Fistula patency 225 days after randomization; ^^Fistula patency 295 days after randomization; ^^^Fistula patency 287 days after randomization ‡Assessed outside window													


Supplemental Table S2: Serious Adverse Events

	Vorapaxar N=6	Placebo N=7
Any Serious Adverse Event	3	3
Aplastic crisis in setting of sickle cell anemia		1*
Superior vena cava syndrome	1	
Melena due to duodenal ulceration		1
Dilation of left ureteral-ileal stricture	1	
Shortness of breath due to volume overload		1
Renal transplant	1	
Clogged nephrostomy tube	1	
Miliary tuberculosis		1
Community acquired pneumonia		1
Severe fever due to catheter infection		1
Abdominal abscess	1^	
Tachycardia		1

*two occurrences in the same participant

^two occurrences in the same participant

Supplemental Figure S1: Study Design of the VorapAccess trial



Abbreviations: AVF, arteriovenous fistula; BARC, Bleeding Academic Research Consortium; GUSTO, Global Utilization Of Streptokinase And Tpa For Occluded Arteries.

Supplemental Figure S2: Cumulative Screening and Enrollment in VorapAccess

